Literature DB >> 12181172

Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum.

E E Daniel1, M Anvari, J E T Fox-Threlkeld, T J McDonald.   

Abstract

Glucagon-like peptide-1 (GLP-1) modulates glucose levels following a meal, including by inhibition of gastric emptying and intestinal transport. Intra-arterial injection of GLP-1 into the gastric corpus, antrum, or pylorus of anesthetized dogs had no effect on the contractile activity of the resting or neurally activated stomach. GLP-1 injected intra-arterially inhibited intestinal segments when activated by enteric nerve stimulation but not by acetylcholine. Isolated ileum segments were perfused intra-arterially, instrumented with strain gauges to record circular muscle activity and with subserosal electrodes to stimulate enteric nerves. GLP-1 caused concentration-dependent inhibition of nerve-stimulated phasic but not tonic activity. This was absent during TTX-induced activity and partly prevented by N(G)-nitro-L-arginine. Exendin-(9-39), the GLP-1 antagonist, had no intrinsic activity and did not affect the actions of GLP-1. Capsaicin mimicked the effects of GLP-1 and may have reduced the effect of subsequent GLP-1. GLP-1 may mediate paracrine action on afferent nerves in the canine ileal mucosa using an unusual receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181172     DOI: 10.1152/ajpgi.00110.2002

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  6 in total

1.  A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells.

Authors:  Y Hattori; T Jojima; A Tomizawa; H Satoh; S Hattori; K Kasai; T Hayashi
Journal:  Diabetologia       Date:  2010-07-01       Impact factor: 10.122

Review 2.  Glucagon-like peptide 1 and appetite.

Authors:  Megan J Dailey; Timothy H Moran
Journal:  Trends Endocrinol Metab       Date:  2013-01-16       Impact factor: 12.015

3.  Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats.

Authors:  Elisabeth L Raab; Patricia M Vuguin; Doris A Stoffers; Rebecca A Simmons
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-10-21       Impact factor: 3.619

4.  Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.

Authors:  C N Andrews; A E Bharucha; M Camilleri; P A Low; B M Seide; D D Burton; K K Nickander; K L Baxter; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2007-09       Impact factor: 3.598

5.  Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

Review 6.  Actions of glucagon-like peptide-1 receptor ligands in the gut.

Authors:  Jens Juul Holst; Daniel Bjørklund Andersen; Kaare Villum Grunddal
Journal:  Br J Pharmacol       Date:  2021-08-04       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.